Mitochondrial diseaseSCHAPIRA, Anthony H. V.Lancet (British edition). 2006, Vol 368, Num 9529, pp 70-82, issn 0140-6736, 13 p.Article

Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease: A Review of Symptomatic and Potential Disease-Modifying EffectsSCHAPIRA, Anthony H. V.CNS drugs. 2011, Vol 25, Num 12, pp 1061-1071, issn 1172-7047, 11 p.Article

Treatment options in the modern management of parkinson diseaseSCHAPIRA, Anthony H. V.Archives of neurology (Chicago). 2007, Vol 64, Num 8, pp 1083-1088, issn 0003-9942, 6 p.Article

Analysis of the trinucleotide CAG repeat from the DNA polymerase γ gene (POLG) in patients with Parkinson's diseaseTAANMAN, Jan-Willem; SCHAPIRA, Anthony H. V.Neuroscience letters. 2005, Vol 376, Num 1, pp 56-59, issn 0304-3940, 4 p.Article

Etiology of Parkinson's diseaseSCHAPIRA, Anthony H. V.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S10-S23, SUP4Article

Neuroprotection and dopamine agonistsSCHAPIRA, Anthony H. V.Neurology. 2002, Vol 58, Num 4, pp S9-S18, issn 0028-3878, SUP1Article

Test for LRRK2 mutations in patients with Parkinson's diseaseHEALY, Daniel G; WOOD, Nicholas W; SCHAPIRA, Anthony H. V et al.Practical neurology (Print). 2008, Vol 8, Num 6, pp 381-385, issn 1474-7758, 5 p.Article

Role of the pharmacist in the effective management of wearing-off in parkinson's diseaseSIMONSON, William; HAUSER, Robert A; SCHAPIRA, Anthony H. V et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 11, pp 1842-1849, issn 1060-0280, 8 p.Article

Fits and strokesSHARMA, Pankaj; TAO WANG; BROWN, Morris J et al.Lancet (British edition). 2001, Vol 358, Num 9276, issn 0140-6736, p. 120Article

Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptorsCHAU, Kai-Yin; PRASAD KORLIPARA, L. V; COOPER, J. Mark et al.Journal of the neurological sciences. 2009, Vol 278, Num 1-2, pp 44-53, issn 0022-510X, 10 p.Article

The Clinical Relevance of Levodopa Toxicity in the Treatment of Parkinson's DiseaseSCHAPIRA, Anthony H. V.Movement disorders. 2008, Vol 23, issn 0885-3185, S515-S520, SUP3Article

Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectivesSCHAPIRA, Anthony H. V; OLANOW, C. Warren; GREENAMYRE, J. Timothy et al.Lancet (British edition). 2014, Vol 384, Num 9942, pp 545-555, issn 0140-6736, 11 p.Article

Drug Selection and Timing of Initiation of Treatment in Early Parkinson's DiseaseSCHAPIRA, Anthony H. V; OLANOW, C. Warren.Annals of neurology. 2008, Vol 64, Num 6, issn 0364-5134, S47-S55, SUPArticle

Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesisCHAU, Kai-Yin; HEY LONG CHING; SCHAPIRA, Anthony H. V et al.Journal of neurochemistry. 2009, Vol 110, Num 3, pp 1005-1013, issn 0022-3042, 9 p.Article

Analysis of the Factors Influencing the Cardiac Phenotype in Friedreich's AtaxiaRAJAGOPALAN, Bheeshma; FRANCIS, Jane M; COOKE, Fraser et al.Movement disorders. 2010, Vol 25, Num 7, pp 846-852, issn 0885-3185, 7 p.Article

Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD StudySCHAPIRA, Anthony H. V; ALBRECHT, Stefan; BARONE, Paolo et al.Movement disorders. 2010, Vol 25, Num 11, pp 1627-1632, issn 0885-3185, 6 p.Article

Coordinating outcomes measurement in ataxia research : Do some widely used generic rating scales tick the boxes?RIAZI, Afsane; CANO, Stefan J; COOPER, J. Mark et al.Movement disorders. 2006, Vol 21, Num 9, pp 1396-1403, issn 0885-3185, 8 p.Article

Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell linesBERETTA, Simone; MATTAVELLI, Laura; SALA, Gessica et al.Brain. 2004, Vol 127, pp 2183-2192, issn 0006-8950, 10 p., 10Article

Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. DiscussionSCHAPIRA, Anthony H. V; OLANOW, C. Warren.Annals of neurology. 2003, Vol 53, pp S149-S159, issn 0364-5134, SUP3Article

Timing of treatment initiation in Parkinson's disease : A need for reappraisal? Authors' replySCHAPIRA, Anthony H. V; OBESO, Jose; AMINOFF, Michael J et al.Annals of neurology. 2006, Vol 59, Num 3, pp 559-565, issn 0364-5134, 7 p.Article

Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitorsMILLER, Robert F; SHAHMANESH, Maryam; HANNA, Michael G et al.Antiviral therapy (London). 2003, Vol 8, Num 3, pp 253-257, issn 1359-6535, 5 p.Article

Parkinsonism in patients with chronic hepatitis C treated with interferon-α2b: a report of two casesKAJIHARA, Mikio; MONTAGNESE, Sara; KHANNA, Pooja et al.European journal of gastroenterology & hepatology. 2010, Vol 22, Num 5, pp 628-631, issn 0954-691X, 4 p.Article

Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagyGEGG, Matthew E; COOPER, J. Mark; CHAU, Kai-Yin et al.Human molecular genetics (Print). 2010, Vol 19, Num 24, pp 4861-4870, issn 0964-6906, 10 p.Article

Why Have We Failed to Achieve Neuroprotection in Parkinson's Disease?OLANOW, C. Warren; KIEBURTZ, Karl; SCHAPIRA, Anthony H. V et al.Annals of neurology. 2008, Vol 64, Num 6, issn 0364-5134, S101-S110, SUPArticle

Patterns of Treatment for Restless Legs Syndrome in Primary Care in the United KingdomMARTINEZ, Carlos; FINNERN, Henrik Walter; RIETBROCK, Stephan et al.Clinical therapeutics. 2008, Vol 30, Num 2, pp 405-418, issn 0149-2918, 14 p.Article